Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours (Q39250672)

10 September 2017

title

Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours (English)

1 reference

10 September 2017

0 references

15

1 reference

10 September 2017

Alex J Eustace

2

0 references

Stephen F Madden

object named as

Stephen Madden

11

0 references

author name string

Brigid C Browne

1

1 reference

10 September 2017

Susan Kennedy

3

1 reference

10 September 2017

Neil A O'Brien

4

1 reference

10 September 2017

Kasper Pedersen

5

1 reference

10 September 2017

Martina S J McDermott

6

1 reference

10 September 2017

Annemarie Larkin

7

1 reference

10 September 2017

Jo Ballot

8

1 reference

10 September 2017

Thamir Mahgoub

9

1 reference

10 September 2017

Francesco Sclafani

10

1 reference

10 September 2017

John Kennedy

12

1 reference

10 September 2017

Michael J Duffy

13

1 reference

10 September 2017

John Crown

14

1 reference

10 September 2017

language of work or name

English

0 references

publication date

2 November 2012

1 reference

Breast Cancer Research and Treatment

10 September 2017

published in

1 reference

10 September 2017

volume

136

1 reference

10 September 2017

issue

3

1 reference

10 September 2017

page(s)

717-727

1 reference

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

10 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2260-9

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2260-9

Humanization of an anti-p185HER2 antibody for human cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2260-9

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2260-9

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2260-9

HER-2 signaling and inhibition in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2260-9

HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2260-9

HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2260-9

Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2260-9

Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2260-9

Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17-allylamino geldanamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2260-9

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2260-9

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2260-9

Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2260-9

Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2260-9

Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2260-9

Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2260-9

Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2260-9

Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2260-9

Dependence of Wilms tumor cells on signaling through insulin-like growth factor 1 in an orthotopic xenograft model targetable by specific receptor inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2260-9

Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2260-9

Co-targeting insulin-like growth factor I receptor and HER2: dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2260-9

PI3K/PTEN/Akt pathway status affects the sensitivity of high-grade glioma cell cultures to the insulin-like growth factor-1 receptor inhibitor NVP-AEW541.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2260-9

Expression of insulin-like growth factor 1 receptor in primary breast cancer: immunohistochemical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2260-9

Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2260-9

Molecular mechanisms involved in activity of h7C10, a humanized monoclonal antibody, to IGF-1 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2260-9

IGF1R signaling in Ewing sarcoma is shaped by clathrin-/caveolin-dependent endocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2260-9

A heterozygous mutation of the insulin-like growth factor-I receptor causes retention of the nascent protein in the endoplasmic reticulum and results in intrauterine and postnatal growth retardation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2260-9

Type 1 insulin-like growth factor receptor translocates to the nucleus of human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2260-9

Evaluation of a breast cancer risk prediction model expanded to include category of prior benign breast disease lesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2260-9

10.1007/S10549-012-2260-9

21 January 2018

Identifiers

DOI

1 reference

10 September 2017

1 reference